Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 3/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683709 | 0.89 | CNR2 (0.48) | FGFR2FGFR3ALDH1A1TP53MAPT | |
| SCHEMBL1683643 | 0.88 | ALDH1A1 (0.41) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL1683954 | 0.86 | EGFR (0.53) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL4423934 | 0.83 | ALDH1A1 (0.50) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL4424310 | 0.78 | FGFR2 (0.38) | FGFR2FGFR3FGFR1MAPT | |
| SCHEMBL4427216 | 0.77 | CNR2 (0.47) | ALDH1A1TP53MAPT | |
| SCHEMBL1683751 | 0.77 | HDAC1 (0.37) | FGFR2FGFR3HDAC1HDAC8HDAC6 | |
| SCHEMBL1683879 | 0.76 | HPGD (0.38) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL9954603 | 0.76 | ALDH1A1 (0.45) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL1683625 | 0.74 | ALDH1A1 (0.52) | EGFRHDAC3HDAC1HDAC7HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| EP-2303021-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2959900-A1 | COMPOUND FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2303021-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | FGFR2 852/4885FGFR3 601/4885EGFR 263/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | FGFR2 346/4885FGFR3 525/4885EGFR 520/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | FGFR2 346/4885FGFR3 525/4885EGFR 520/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | FGFR2 346/4885FGFR3 525/4885EGFR 520/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | FGFR2 346/4885FGFR3 525/4885EGFR 520/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | FGFR2 346/4885FGFR3 525/4885EGFR 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.